Molecular Docking and Network Pharmacology Interaction Analysis of Gingko Biloba (EGB761) Extract with Dual Target Inhibitory Mechanism in Alzheimer’s Disease
Restricted accessResearch articleFirst published online May 16, 2023
Molecular Docking and Network Pharmacology Interaction Analysis of Gingko Biloba (EGB761) Extract with Dual Target Inhibitory Mechanism in Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common type of neurodegenerative dementia affecting people in their later years of life. The AD prevalence rate has significantly increased due to a lack of early detection technology and low therapeutic efficacy. Despite recent scientific advances, some aspects of AD pathological targets still require special attention. Certain traditionally consumed phytocompounds have been used for thousands of years to treat such pathologies. The standard extract of Gingko biloba (EGB761) is a combination of 13 macro phyto-compounds and various other micro phytocompounds that have shown greater therapeutic potential against the pathology of AD.
Objective:
Strong physiological evidence of cognitive health preservation has been observed in elderly people who keep an active lifestyle. According to some theories, consuming certain medicinal extracts helps build cognitive reserve. We outline the research employing EGB761 as a dual target for AD.
Methods:
This study investigates various inhibitory targets against AD using computational approaches such as molecular docking, network pharmacology, ADMET (full form), and bioactivity prediction of the selected compounds.
Results:
After interaction studies were done for all the phytoconstituents of EGB761, it was concluded that all four of the phytocompounds (kaempferol, isorhamnetin, quercetin, and ginkgotoxin) showed the maximum inhibitory activity against acetylcholinesterase (AChE) and GSK3β.
Conclusion:
The highly active phytocompounds of EGB761, especially quercetin, kaempferol, and isorhamnetin, have better activity against AChE and GSK3β than its reported synthetic drug, according to molecular docking and network pharmacology research. These compounds may act on multiple targets in the protein network of AD. The AChE theory was primarily responsible for EGB761’s therapeutic efficacy in treating AD.
Wyss-CorayT (2016) Ageing, neurodegeneration and brain rejuvenation. Nature539, 180–186.
2.
AgarwalV, JindalD, AgarwalS, ManiS, SinghM (2021) Initiation of neurodegenerative disorders (NDDs) through metal toxicity generated oxidative stress. In Free Radical Biology and Environmental Toxicity. Molecular and Integrative Toxicology, Kesari KK, Jha NK, eds. Springer, Cham, pp. 263-277.
3.
KarantzoulisS, GalvinJE (2011) Distinguishing Alzheimer’s disease from other major forms of dementia. Expert Rev Neurother11, 1579–1591.
4.
MurphyMP, LeVineH, 3rd (2010) Alzheimer’s disease and the amyloid-beta peptide. J Alzheimers Dis19, 311–323.
5.
ManiS, JindalD, SinghM (2023) Gene therapy, a potential therapeutic tool for neurological and neuropsychiatric disorders: Applications, challenges and future prospective. Curr Gene Ther23, 20–40.
6.
MohandasE, RajmohanV, RaghunathB (2009) Neurobiology of Alzheimer’s disease. Indian J Psychiatry51, 55–61.
7.
Gomez-SintesR, HernandezF, LucasJ, AvilaJ (2011) GSK-3 mouse models to study neuronal apoptosis and neurodegeneration. Front Mol Neurosci4, 45.
8.
Morales-GarciaJA, Luna-MedinaR, Alonso-GilS, Sanz-SancristobalM, PalomoV, GilC, SantosA, MartinezA, Perez-CastilloA (2012) Glycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in vitro and in vivo. ACS Chem Neurosci3, 963–971.
9.
RippinI, Eldar-FinkelmanH (2021) Mechanisms and therapeutic implications of GSK-3 in treating neurodegeneration. Cells10, 262.
10.
Eldar-FinkelmanH, MartinezA (2011) GSK-3 inhibitors: Preclinical and clinical focus on CNS. Front Mol Neurosci4, 32.
11.
HampelH, MesulamMM, CuelloAC, FarlowMR, GiacobiniE, GrossbergGT, KhachaturianAS, VergalloA, CavedoE, SnyderPJ, KhachaturianZS (2018) The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain141, 1917–1933.
12.
FrancisPT, PalmerAM, SnapeM, WilcockGK (1999) The cholinergic hypothesis of Alzheimer’s disease: A review of progress. J Neurol Neurosurg Psychiatry66, 137–147.
GrossbergGT (2003) Cholinesterase inhibitors for the treatment of Alzheimer’s disease: Getting on and staying on. Curr Ther Res Clin Exp64, 216–235.
15.
HansenRA, GartlehnerG, WebbAP, MorganLC, MooreCG, JonasDE (2008) Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis. Clin Interv Aging3, 211–225.
16.
OlivaresD, DeshpandeVK, ShiY, LahiriDK, GreigNH, RogersJT, HuangX (2012) N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer’s disease, vascular dementia and Parkinson’s disease. Curr Alzheimer Res9, 746–758.
DereureO (2001) Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment. Am J Clin Dermatol2, 253–262.
19.
GuengerichFP (2011) Mechanisms of drug toxicity and relevance to pharmaceutical development. Drug Metab Pharmacokinet26, 3–14.
20.
Amat-Ur-RasoolH, AhmedM, HasnainS, AhmedA, CarterWG (2021) In silico design of dual-binding site anti-cholinesterase phytochemical heterodimers as treatment options for Alzheimer’s disease. Curr Issues Mol Biol44, 152–175.
21.
SarkarB, AlamS, RajibTK, IslamSS, ArafY, UllahMA (2021) Identification of the most potent acetylcholinesterase inhibitors from plants for possible treatment of Alzheimer’s disease: A computational approach. Egypt J Med Hum Genet22, 10.
22.
ShenZJ, FuYB, HouJL, LinLN, WangXY, LiCY, YangYX (2022) Integrating network pharmacology, UPLC-Q–TOF–MS and molecular docking to investigate the effect and mechanism of Chuanxiong Renshen decoction against Alzheimer’s disease. Chin Med17, 143.
23.
de SousaNF, ScottiL, de MouraÉP, Dos Santos MaiaM, RodriguesGCS, de MedeirosHIR, LopesSM, ScottiMT (2022) Computer aided drugdesign methodologies with natural products in the drug researchagainst Alzheimer’s disease. Curr Neuropharmacol20, 857–885.
24.
ChoJH, SungJH, ChoEH, WonCK, LeeHJ, KimMO, KohPO (2009) Gingko biloba Extract (EGb 761) prevents ischemic brain injury by activation of the Akt signaling pathway. Am J Chin Med37, 547–555.
25.
KomboHZ, KumarS, SinghG (2022) Traditional medicines and experimental analysis methods for Alzheimer’s disease. Tradit Med Res7, 43.
SinghSK, SrivastavS, CastellaniRJ, Plascencia-VillaG, PerryG (2019) Neuroprotective and antioxidant effect of ginkgo biloba extract against AD and other neurological disorders. Neurotherapeutics16, 666–674.
28.
DeFeudisFV, DrieuK (2000) Ginkgo biloba extract (EGb 761) and CNS functions: Basic studies and clinical applications. Curr Drug Targets1, 25–58.
29.
BeckSM, RugeH, SchindlerC, BurkartM, MillerR, KirschbaumC, GoschkeT (2016) Effects of Ginkgo biloba extract EGb 761®on cognitive control functions, mental activity of the prefrontalcortex and stress reactivity in elderly adults with subjectivememory impairment - a randomized double-blind placebo-controlledtrial. Hum Psychopharmacol31, 227–242.
30.
SinghM, SinghSP, RachanaR (2017) Development, characterization and cytotoxicity evaluation of Gingko biloba extract (EGB761) loaded microemulsion for intra-nasal application. J Appl Pharm Sci7, 024–034.
31.
GerlitsO, HoK-Y, ChengX, BlumenthalD, TaylorP, KovalevskyA, RadićZ (2019) A new crystal form of human acetylcholinesterase for exploratory room-temperature crystallography studies. Chem Biol Interact309, 108698.
SastryGM, AdzhigireyM, DayT, AnnabhimojuR, ShermanW (2013) Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des27, 221–234.
35.
JacobsonMP, FriesnerRA, XiangZ, HonigB (2002) On the role of the crystal environment in determining protein side-chain conformations. J Mol Biol320, 597–608.
36.
BanT, OhueM, AkiyamaY (2018) Multiple grid arrangement improves ligand docking with unknown binding sites: Application to the inverse docking problem. Comput Biol Chem73, 139–146.
37.
FriesnerRA, MurphyRB, RepaskyMP, FryeLL, GreenwoodJR, HalgrenTA, SanschagrinPC, MainzDT (2006) Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein–ligand complexes. J Med Chem49, 6177–6196.
38.
HarderE, DammW, MapleJ, WuC, ReboulM, XiangJY, WangL, LupyanD, DahlgrenMK, KnightJL, KausJW, CeruttiDS, KrilovG, JorgensenWL, AbelR, FriesnerRA (2016) OPLS3: A force field providing broad coverage of drug-like small molecules and proteins. J Chem Theory Comput12, 281–296.
39.
FriesnerRA, BanksJL, MurphyRB, HalgrenTA, KlicicJJ, MainzDT, RepaskyMP, KnollEH, ShelleyM, PerryJK, ShawDE, FrancisP, ShenkinPS (2004) Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem47, 1739–1749.
40.
DainaA, MichielinO, ZoeteV (2017) SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep7, 42717.
41.
SmithML, LanciaJK, MercerTI, IpC (2004) Selenium compounds regulate p53 by common and distinctive mechanisms. Anticancer Res24, 1401–1408.
42.
BanerjeeP, EckertAO, SchreyAK, PreissnerR (2018) ProTox-II: A webserver for the prediction of toxicity of chemicals. Nucleic Acids Res46, W257–W263.
GfellerD, GrosdidierA, WirthM, DainaA, MichielinO, ZoeteV (2014) SwissTargetPrediction: A web server for target prediction of bioactive small molecules. Nucleic Acids Res42, W32–38.
51.
ShannonP, MarkielA, OzierO, BaligaNS, WangJT, RamageD, AminN, SchwikowskiB, IdekerT (2003) Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res13, 2498–2504.
KhanMT, OrhanI, SenolFS, KartalM, SenerB, DvorskáM, SmejkalK, SlapetováT (2009) Cholinesterase inhibitoryactivities of some flavonoid derivatives and chosen xanthone andtheir molecular docking studies. Chem Biol Interact181, 383–389.
57.
JoshiA, VatsN, SinghH, KaushikV (2022) Quercetin compound analysis to develop treatment for dementia associated with Alzheimer’s disease in humans: In-silico study. J Drug Alcohol Res11, 236174.
58.
ChenY, FengZ, ShenM, LinW, WangY, WangS, LiC, WangS, ChenM, ShanW, XieX-Q (2020) Insight into Ginkgo biloba L. extract on the improved spatial learning and memory by chemogenomics knowledgebase, molecular docking, molecular dynamics simulation, and bioassay validations. ACS Omega5, 2428–2439.
59.
ZhangW, LvM, ShiY, MuY, YaoZ, YangZ (2021) Network pharmacology-based study of the underlying mechanisms of Huangqi Sijunzi decoction for Alzheimer’s disease. Evid Based Complement Alternat Med2021, 6480381.
60.
AlamA, TamkeenN, ImamN, FarooquiA, AhmedMM, TazyeenS, AliS, MalikMZ, IshratR (2018) Pharmacokinetic and molecular docking studies of plant-derived natural compounds to exploring potential anti-Alzheimer activity. In In Silico Approach for Sustainable Agriculture, Choudhary D, Kumar M, Prasad R, Kumar V, eds. Springer, Singapore, pp. 217–238.
61.
OjoES, TischkauSA (2021) The role of AhR in the hallmarks of brain aging: Friend and foe. Cells10, 2729.
62.
AngelovaPR, AbramovAY (2018) Role of mitochondrial ROS in the brain: From physiology to neurodegeneration. FEBS Lett592, 692–702.
63.
GreeneND, StanierP, MooreGE (2011) The emerging role of epigenetic mechanisms in the etiology of neural tube defects. Epigenetics6, 875–883.
64.
RosenkranzSC, ShaposhnykovAA, TrägerS, EnglerJB, WitteME, RothV, VieiraV, PaauwN, BauerS, Schwencke-WestphalC, SchubertC, BalLC, SchattlingB, PlessO, van HorssenJ, FreichelM, FrieseMA (2021) Enhancing mitochondrial activity in neurons protects against neurodegeneration in a mouse model of multiple sclerosis. Elife10, e61798.
65.
BastianettoS, RamassamyC, DoréS, ChristenY, PoirierJ, QuirionR (2000) The Ginkgo biloba extract (EGb 761) protectshippocampal neurons against cell death induced by beta-amyloid. Eur J Neurosci12, 1882–1890.
66.
JiangXY, ChenTK, ZhouJT, HeSY, YangHY, ChenY, QuW, FengF, SunHP (2018) Dual GSK-3β/AChE inhibitors as a new strategy for multitargeting anti-Alzheimer’s disease drug discovery. ACS Med Chem Lett9, 171–176.
67.
RajmohanR, ReddyPH (2017) Amyloid-beta and phosphorylated tau accumulations cause abnormalities at synapses of Alzheimer’s disease neurons. J Alzheimers Dis57, 975–999.
68.
De SarnoP, BijurGN, ZmijewskaAA, LiX, JopeRS (2006) In vivo regulation of GSK3 phosphorylation by cholinergic and NMDA receptors. Neurobiol Aging27, 413–422.
69.
JingP, JinQ, WuJ, ZhangX-J (2008) GSK3β mediates the induced expression of synaptic acetylcholinesterase during apoptosis. J Neurochem104, 409–419.
